“…Very recently, three papers were published describing TadA8e fused with different Cas9 variants, including SpRY, SpG, SpCas9‐NRRH, SpCas9‐NRTH and SpCas9‐NRCH for A‐to‐G base editing (Li et al, 2020; Ren et al, 2021; Xu et al, 2021). In agreement with our results, TadA8e showed high editing efficiencies in these different systems, especially when fused with SpG, SpCas9‐NRRH, SpCas9‐NRTH, and SpCas9‐NRCH, and its homozygous substitution rate was as high as 66.7% for a specific target (Li et al, 2020).…”